Chemotherapy Induced Anemia - Pipeline Review, H2 2015

Date: September 16, 2015
Pages: 67
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: CF002BB42A3EN
Leaflet:

Download PDF Leaflet

Chemotherapy Induced Anemia - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Chemotherapy Induced Anemia - Pipeline Review, H2 2015’, provides an overview of the Chemotherapy Induced Anemia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Anemia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Anemia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Chemotherapy Induced Anemia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Chemotherapy Induced Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Chemotherapy Induced Anemia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Anemia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Anemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Chemotherapy Induced Anemia Overview
Therapeutics Development
Pipeline Products for Chemotherapy Induced Anemia - Overview
Pipeline Products for Chemotherapy Induced Anemia - Comparative Analysis
Chemotherapy Induced Anemia - Therapeutics under Development by Companies
Chemotherapy Induced Anemia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Chemotherapy Induced Anemia - Products under Development by Companies
Chemotherapy Induced Anemia - Companies Involved in Therapeutics Development
3SBIO INC.
Aprogen, Inc.
Avesthagen Limited
BIOCAD
Dr. Reddy's Laboratories Limited
Hospira, Inc.
Panacea Biotec Limited
ProMetic Life Sciences Inc.
Sandoz International GmbH
Therapure Biopharma Inc.
Tolero Pharmaceuticals, Inc.
Chemotherapy Induced Anemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
darbepoetin alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
darbepoetin alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
darbepoetin alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
darbepoetin alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
darbepoetin alfa (recombinant) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
epoetin alfa (recombinant) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
epoetin zeta - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PBI-1402 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PBI-4494 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PRS-080 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SSS-06 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TBI-304H - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TP-0184 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TP-0413 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TXA-302 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chemotherapy Induced Anemia - Recent Pipeline Updates
Chemotherapy Induced Anemia - Dormant Projects
Chemotherapy Induced Anemia - Dormant Projects
Chemotherapy Induced Anemia - Discontinued Products
Chemotherapy Induced Anemia - Product Development Milestones
Featured News & Press Releases
Mar 11, 2015: Therapure Innovations Receives FDA Approval to Proceed with a Phase 1 Clinical Trial of Its Novel Anemia Therapeutic TBI 304H
Sep 30, 2010: Safety study for subcutaneous epoetin alfa biosimilar Binocrit/Epoetin alfa Hexal/Abseamed suspended
Aug 09, 2010: Dr Reddy’s Launches Darbepoetin Alfa For Treatment Of Anemia In India
Feb 22, 2010: Retacrit Received a Positive Opinion From the European Committee for Medicinal Products for Human Use (CHMP) for Subcutaneous (SC) use in Renal Anaemia
Dec 01, 2008: International presentation of clinical safety and efficacy data for Binocrit, the world’s first complex biosimilar
Jan 07, 2008: Sandoz and Gambro form strategic alliance
Dec 19, 2007: Hospira's Retacrit Receives Marketing Authorization in the EU
Oct 18, 2007: Hospira's Biosimilar Epoetin Retacrit Receives Positive Opinion Recommending EU Approval
Aug 31, 2007: European Commission approves Sandoz's epoetin alfa Binocrit
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Chemotherapy Induced Anemia, H2 2015
Number of Products under Development for Chemotherapy Induced Anemia - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Chemotherapy Induced Anemia - Pipeline by 3SBio Inc., H2 2015
Chemotherapy Induced Anemia - Pipeline by Aprogen, Inc., H2 2015
Chemotherapy Induced Anemia - Pipeline by Avesthagen Limited, H2 2015
Chemotherapy Induced Anemia - Pipeline by BIOCAD, H2 2015
Chemotherapy Induced Anemia - Pipeline by Dr. Reddy's Laboratories Limited, H2 2015
Chemotherapy Induced Anemia - Pipeline by Hospira, Inc., H2 2015
Chemotherapy Induced Anemia - Pipeline by Panacea Biotec Limited, H2 2015
Chemotherapy Induced Anemia - Pipeline by ProMetic Life Sciences Inc., H2 2015
Chemotherapy Induced Anemia - Pipeline by Sandoz International GmbH, H2 2015
Chemotherapy Induced Anemia - Pipeline by Therapure Biopharma Inc., H2 2015
Chemotherapy Induced Anemia - Pipeline by Tolero Pharmaceuticals, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Chemotherapy Induced Anemia Therapeutics - Recent Pipeline Updates, H2 2015
Chemotherapy Induced Anemia - Dormant Projects, H2 2015
Chemotherapy Induced Anemia - Discontinued Products, H2 2015

LIST OF FIGURES

Number of Products under Development for Chemotherapy Induced Anemia, H2 2015
Number of Products under Development for Chemotherapy Induced Anemia - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

3SBio Inc.
Aprogen, Inc.
Avesthagen Limited
BIOCAD
Dr. Reddy's Laboratories Limited
Hospira, Inc.
Panacea Biotec Limited
ProMetic Life Sciences Inc.
Sandoz International GmbH
Therapure Biopharma Inc.
Tolero Pharmaceuticals, Inc.
Skip to top


Ask Your Question

Chemotherapy Induced Anemia - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: